Cernilton tablets for prostatitis and prostatic hyperplasia (cernitin pollen extract)

General information on Japanese Cernilton tablets for prostatitis and prostatic hyperplasia (cernitin pollen extract)

Package details: 100 tablets

Manufacturer: Fuso Pharmaceutical Industries, Ltd., Japan

Active ingredient: cernitin pollen extract

Medical effect: Cernilton tablets are effective for the treatment of chronic prostatitis and benign prostatic hyperplasia at early stage

Contraindications and precautions: do not use for pregnant and breastfeeding women.  Store away from direct sunlight, heat and moisture. In case of moisture absorption the medicine may change color.

If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration

For adults, take 2 tablets at a time, 2 or 3 times a day. The doctor in charge may adjust the dosage according to symptoms.

How effective are Cernilton tablets from Japan for prostatitis and prostatic hyperplasia (cernitin pollen extract)?

Cernilton tablets contain an extract of rye grass flower pollen. This ingredient has been used to treat prostatitis and benign prostatic hyperplasia in Europe for more than 40 years. Cernilton tablets help to reduce such symptoms as:

• difficulty in micturition,
• pollakiuria,
• residual urine,
• feeling of residual urine,
• micturition pain,
• week urinary stream,
• perineal discomfort.

Who should take Cernilton tablets from Japan?

Cernilton tablets are effective for the treatment of chronic prostatitis and benign prostatic hyperplasia at early stage. Studies showed that cernitin pollen extract provides overall clinical efficacy in 85% of cases, showing particularly good results for urine maximum flow rate, average flow rate and residual urine volume (R. Yasumoto, H. Kawanishi et al. “Clinical evaluation of long-term treatment using cernitin pollen extract in patients with benign prostatic hyperplasia”. Clinical therapeutics, 1995, 17(1): 82-87).